Stocks:
5,168
ETFs:
2,288
Exchanges:
11
Market Cap:
$63.92T
24h Vol:
$4.36B
Dominance:
MSFT:4.92%
Stocklytics Platform
Instrument logo  EXAS
Exact Sciences Corp
EXAS
70 / 100
$71.34arrow_drop_down2.20%-$1.61

Performance History

Stocklytics logo
Key Stats
Open$72.92
Prev. Close$72.95
EPS-1.13
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$13.36B
PE Ratio-
LOWHIGH
Day Range70.79
73.09
52 Week Range56.05
100.77
Ratios
P/B Ratio4.25
Revenue$2.49B
Operating M. %-11.94%
Earnings$0.00
Earnings Growth %67.26%
EBITDA Margin %-4.09%
ROE %-6.60%
EPS-1.13

Score Breakdown

70vs 55. Market Avg.

All Score 70 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

EXASMARKET
Value3640
Quality6340
Ownership3817
Growth6745
Dividends-37
check_circle

Exact Sciences Corp's Sales growth rate in the last 3 years of 18.94% is great compared to market average of 17.49%. This indicates EXAS could be a good value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$751.62
24H (%)arrow_drop_down1.04%
24H ($)-$7.97
MARKET CAP$724.46B
PRICE$438.91
24H (%)arrow_drop_down0.63%
24H ($)-$2.81
MARKET CAP$414.91B
PRICE$147.57
24H (%)arrow_drop_down0.81%
24H ($)-$1.21
MARKET CAP$361.94B
PRICE$126.33
24H (%)arrow_drop_up0.14%
24H ($)$0.18
MARKET CAP$321.01B

About Exact Sciences Corp (EXAS)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Sector
Healthcare
Industry
Diagnostics & Research
CEO
Mr. Kevin T. Conroy
Headquarters
Madison
Employees
6300
Exchange
NASDAQ
add Exact Sciences Corp to watchlist

Keep an eye on Exact Sciences Corp

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Exact Sciences Corp's (EXAS) price per share?

The current price per share for Exact Sciences Corp (EXAS) is $71.34. The stock has seen a price change of -$1.61 recently, indicating a -2.21% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Exact Sciences Corp (EXAS)?

For Exact Sciences Corp (EXAS), the 52-week high is $100.77, which is 41.25% from the current price. The 52-week low is $56.05, the current price is 27.28% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Exact Sciences Corp (EXAS) a growth stock?

Exact Sciences Corp (EXAS) has shown an average price growth of -12.45% over the past three years. It has received a score of 34 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Exact Sciences Corp as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Exact Sciences Corp (EXAS) stock price performance year to date (YTD)?

As of the latest data, Exact Sciences Corp (EXAS) has a year-to-date price change of -3.25%. Over the past month, the stock has experienced a price change of 17.53%. Over the last three months, the change has been 6.27%. Over the past six months, the figure is 10.47%. Looking at a longer horizon, the five-year price change stands at -24.83%.

help
Is Exact Sciences Corp (EXAS) a profitable company?

Exact Sciences Corp (EXAS) has a net income of -$204.15M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 73.83% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -11.94% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $2.5B, with a revenue growth rate of 19.93%, providing insight into the company's sales performance and growth. The gross profit is $1.85B. Operating income is noted at -$215.01M. Furthermore, the EBITDA is -$102.23M.

help
What is the market capitalization of Exact Sciences Corp (EXAS)?

Exact Sciences Corp (EXAS) has a market capitalization of $13.36B. The average daily trading volume is 3.69M, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.